Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-deficient or platinum-sensitive solid tumors Etude de phase II multi-cohorte (multicentrique évaluant l'efficacité et la sécurité d'emploi de la combinaison rucaparib (inhibiteur de PARP) et atezolizumab (anticorps anti-PD-L1) chez des patients dont la tumeur présente un défaut de réparation de l'ADN ou est sensible aux sels de platine).

Trial Profile

A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-deficient or platinum-sensitive solid tumors Etude de phase II multi-cohorte (multicentrique évaluant l'efficacité et la sécurité d'emploi de la combinaison rucaparib (inhibiteur de PARP) et atezolizumab (anticorps anti-PD-L1) chez des patients dont la tumeur présente un défaut de réparation de l'ADN ou est sensible aux sels de platine).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Rucaparib (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ARIANES
  • Most Recent Events

    • 10 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top